Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2009
12/31/2009US20090324602 Anti-fn14 antibodies and uses thereof
12/31/2009US20090324601 Targeted binding agents directed to pdgfr-alpha and uses thereof
12/31/2009US20090324600 Use of an anti-cd151 antibody in the treatment of cancer
12/31/2009US20090324599 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity
12/31/2009US20090324598 Method for the treatment of inflammatory disorders
12/31/2009US20090324597 Unique long 16 (UL-16)-binding proteins (ULBP) specific immunoglobulin for use in diganosis cell proliferative disorders
12/31/2009US20090324596 Methods of identifying and treating poor-prognosis cancers
12/31/2009US20090324595 Cancer prognostic diagnostic and treatment methods
12/31/2009US20090324594 Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells
12/31/2009US20090324593 Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
12/31/2009US20090324592 Compositions and methods for the diagnosis and treatment of tumor
12/31/2009US20090324591 Treatment of pulmonary disease conditions
12/31/2009US20090324590 Myostatin antagonists
12/31/2009US20090324589 Methods for controlling blood pharmacokinetics of antibodies
12/31/2009US20090324588 Treating Inflammatory Disorders With Antibodies to the Alpha-7 Nicotinic Receptors
12/31/2009US20090324587 Cancer Therapies and Pharmaceutical Compositions Used Therein
12/31/2009US20090324586 Lyophilization cycle robustness strategy
12/31/2009US20090324585 Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
12/31/2009US20090324584 Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant
12/31/2009US20090324583 Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation
12/31/2009US20090324582 Process for identification of molecular mimicry and the uses thereof
12/31/2009US20090324581 Heteroarylamide lower carboxylic acid derivative
12/31/2009US20090324580 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
12/31/2009US20090324579 Anti-apoptotic protein antibodies
12/31/2009US20090324556 Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof
12/31/2009US20090324544 Substituted cyclic pyrrolidine derivatives
12/31/2009US20090324540 Compounds and compositions for delivering active agents
12/31/2009US20090324512 Polypeptide constructs for nasal administration
12/31/2009US20090324501 Vaccine Carrier
12/31/2009US20090324492 Treatment for Central Nervous System Disorders
12/31/2009US20090324491 Diagnosis and Treatment of Cancer Using Anti-EREG Antibody
12/31/2009US20090324490 Compositions and methods for the diagnosis and treatment of tumor
12/31/2009US20090324489 Wortmannin conjugates and uses thereof
12/30/2009WO2009158682A2 Compositions and methods for diagnosing and treating pathogenic disorders
12/30/2009WO2009158618A2 Unique avian reoviridae
12/30/2009WO2009158614A1 Novel astrovirus
12/30/2009WO2009158529A2 Lyophilization cycle robustness strategy
12/30/2009WO2009158432A2 Ang-2 inhibition to treat multiple sclerosis
12/30/2009WO2009158395A1 Compositions and methods for enhanced somatostatin immunogenicity
12/30/2009WO2009158240A1 Salmonella vectored vaccines against chlamydia and methods of use
12/30/2009WO2009158142A1 Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
12/30/2009WO2009158035A2 Methods for dosing an activin-actriia antagonist and monitoring of treated patients
12/30/2009WO2009158033A2 Antagonists of activin-actriia and uses for increasing red blood cell levels
12/30/2009WO2009158025A2 Methods for dosing an actriib antagonist and monitoring of treated patients
12/30/2009WO2009158015A2 Antagonists of actriib and uses for increasing red blood cell levels
12/30/2009WO2009157926A1 Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof
12/30/2009WO2009157919A1 SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
12/30/2009WO2009156994A1 Ccl20-specific antibodies for cancer therapy
12/30/2009WO2009156960A2 Novel adjuvant compositions
12/30/2009WO2009156852A1 Rapid responses to delayed booster immunisations
12/30/2009WO2009156448A1 Attenuated pestivirus
12/30/2009WO2009156405A1 Novel immunoadjuvant flagellin-based compounds and use thereof
12/30/2009WO2009156307A1 Probiotics, secretory iga and infection
12/30/2009WO2009156301A1 Probiotics, secretory iga and inflammation
12/30/2009WO2009155962A1 Use
12/30/2009WO2009155886A2 Ferritin 2 for the host immunization against ticks
12/30/2009WO2009155726A2 Humanization of rabbit antibodies using a universal antibody framework
12/30/2009WO2009155724A2 Stable and soluble antibodies inhibiting vegf
12/30/2009WO2009155723A2 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
12/30/2009WO2009155669A1 Method of treatment of vascular complications
12/30/2009WO2009155665A1 Methods and compositions for treating pathological infections
12/30/2009WO2009139853A3 Human monoclonal antibodies against human chemokine receptor ccr7
12/30/2009WO2009137044A3 Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
12/30/2009WO2009132283A3 Method for treating autoimmune disorders
12/30/2009WO2009132081A3 Monoclonal antibody-based targeting of folate receptors
12/30/2009WO2009131606A3 Viral inactivation using crosslinkers and detergents
12/30/2009WO2009126965A3 Compositions, methods and uses for modulations of brca1
12/30/2009WO2009126934A3 Detection and tratment of pancreatic, ovarian and other cancers
12/30/2009WO2009126698A3 Regulation of fatty acid transporters
12/30/2009WO2009126356A3 Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
12/30/2009WO2009124294A3 Pharmaceutical compositions for binding sphingosine-1-phosphate
12/30/2009WO2009120927A3 Methods of treatment
12/30/2009WO2009120380A3 Recombinant rhinovirus vectors
12/30/2009WO2009117661A3 Carrier neutralization assay
12/30/2009WO2009116983A3 Compositions and methods for treating ebola virus infection
12/30/2009WO2009114875A3 Oxidized paraoxonase 1 and paraoxonase 1/hdl particle number ratio as risk markers for cardiovascular disease
12/30/2009WO2009114202A3 Vaccine and immunization method using plasmodium antigen 2
12/30/2009WO2009111304A3 A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
12/30/2009WO2009079585A3 Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
12/30/2009WO2009073179A3 Chlamydia antigens
12/30/2009WO2009070753A3 Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject
12/30/2009WO2009070507A3 Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma
12/30/2009WO2009065054A3 Antibodies specific for the protofibril form of beta-amyloid protein
12/30/2009WO2009058383A3 Ligand
12/30/2009WO2009055688A3 Vaccine targets and delivery systems for cryptosporidium
12/30/2009WO2009055656A3 Vectors, host cells, and methods of production and uses
12/30/2009WO2009039192A3 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
12/30/2009WO2009036246A3 Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
12/30/2009WO2009033183A3 Compounds and methods for treatment of hcv and conditions associated with cd81 binding
12/30/2009WO2009032949A3 High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
12/30/2009WO2009032470A3 Compositions and methods for diagnosing and treating community-acquired methicillin-resistant staphylococcus aureus
12/30/2009WO2009026117A3 Novel compounds
12/30/2009WO2009025867A3 Compositions of humanized notch fusion proteins and methods of treatment
12/30/2009WO2009020643A3 Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue
12/30/2009WO2009014919A3 H2n3 influenza a viruses and methods of use
12/30/2009WO2009012487A3 Chimeric varicella zoster virus-virus like particles
12/30/2009WO2009008912A3 Mycobacterial mutants inducing il-12
12/30/2009WO2009006359A8 Anti- mcp-1 antibodies, compositions, methods and uses
12/30/2009WO2008153772A3 Chlamydia vaccine comprising htra polypeptides
12/30/2009WO2008153655A3 Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic fhv-1 infections, and preventing or treating conjunctivitis
1 ... 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 ... 1823